Among middle-aged and older men with hypogonadism who had or were at increased risk of CVD, the incidence of high-grade or any prostate cancer in TRT-treated men with a baseline PSA concentration less than 3.0 ng/mL was low and not significantly different from that in placebo-treated men. This evidence concerns the gene KLK3 and prostate carcinoma.